Abstract

To investigate the effect of bevacizumab on epithelial ovarian cancer by regulating vascular endothelial growth factor/vascular endothelial growth factor receptor and phosphoinositide 3-kinase/protein kinase B pathway. OVCAR3 cells were divided into control (group A) and experimental (group B) group. The group A did not receive any treatment, while the group B treated human ovarian cancer cells OVCAR3 with bevacizumab. The cell proliferation was detected by cell counting kit 8, the cell migration and invasion were detected by Transwell assay, and the apoptosis was detected by flow cytometry. The expression of proteins was detected by Western blot. The proliferation, migration and invasion of ovarian cancer cells in the group B were decreased. The apoptosis rate of ovarian cancer cells in the group B was increased, the phosphorylated-phosphoinositide 3-kinase and phosphorylated-protein kinase B protein in the group B was reduced than group A. The vascular endothelial growth factor in ovarian cancer cells in the group B was down-regulated and the vascular endothelial growth factor receptor was increased. Bevacizumab inhibits the development and metastasis of ovarian cancer by regulating vascular endothelial growth factor/vascular endothelial growth factor receptor and phosphoinositide 3-kinase/protein kinase B pathways, which may be a potential strategy for the treatment of the disease.